Adverse events associated with BNT162b2 vaccination ID’d
Aug 27, 2021
Vaccination with the Pfizer–BioNTech mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with an increased risk for myocarditis and lymphadenopathy, according...
Hiring frenzy: Brookdale and other senior living operators seek to address labor shortage with displaced...
By
Amy Novotney
Apr 09, 2020
Senior living companies across the country have begun using the COVID-19 pandemic as an opportunity to fill workforce vacancies with employees who have been laid off from other sectors. Top candidates...
Aging services leaders urge Biden administration to prioritize homebound seniors for vaccines
By
Joe Jancsurak
Mar 12, 2021
Four leading aging services organizations this week pressed the Biden administration to prioritize certain vulnerable older Americans, such as homebound seniors and home health care workers, in the vaccination...
Senior living operators protected from liability for COVID-19 ‘covered countermeasures,’ HHS says
By
Kimberly Bonvissuto
Jan 15, 2021
A federal advisory opinion on immunity protections for healthcare professionals related to COVID-19 covered countermeasures had an assist from a senior living industry association.
House passes two bills supporting affordable seniors housing
By
Amy Novotney
Jul 06, 2020
Affordable senior housing received a strong boost of support from the House last week as lawmakers passed two pieces of legislation: the Emergency Housing Protections and Relief Act of 2020 and the Moving...
Paxlovid soon will not be free for Americans
Dec 07, 2022
At this point, about 6 million Americans have taken free Paxlovid doses.
Higher dose of steroid does not improve outcomes in severe COVID-19
Oct 29, 2021
The number of days alive without life support at day 28 did not differ with dexamethasone 12 mg versus 6 mg in those with severe hypoxemia.
Reformulated booster shots ready by September, White House says
Jul 29, 2022
The Biden administration is working on contracts for the reformulated booster doses.
Natural protection against reinfection with BA.1 COVID-19 variant lower
Feb 17, 2023
However, protection against severe disease remains high, at 88.9%, for omicron BA.1 at 40 weeks.
Risk for progression to severe COVID-19 lower with nirmatrelvir + ritonavir
Mar 01, 2022
Treatment of symptomatic COVID-19 with nirmatrelvir plus ritonavir was linked to an 89% lower risk for progression versus placebo.